Letter by Freeman et al Regarding Article, “Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial”

Freeman, William D.; Kuo, Ruth; Aguilar, Maria I.

doi:10.1161/strokeaha.112.660407

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Newly released information prompted the authors to repeat the analysis, incorporating the US cost of dabigatran 150 mg and follow-up RE-LY trial results, which yielded a reduced ICER value of $12 386 per QALY gained. 36 In a similar study conducted by Kamel et al, 13 the authors found the ICER between dabigatran 150 mg and warfarin was $25 000 per QALY gained. The adjusted ICER value reported by Freeman et al and study results from Kamel et al indicate dabigatran is a cost-effective alternative to warfarin, which is a similar finding to this study.…”

Section: Discussionmentioning

confidence: 87%

“…The results from this study may be interpreted in light of previous analyses conducted from a US perspective. In their original study, Freeman et al 36 reported a baseline ICER of $45 372 per QALY gained for dabigatran 150 mg compared with warfarin. Newly released information prompted the authors to repeat the analysis, incorporating the US cost of dabigatran 150 mg and follow-up RE-LY trial results, which yielded a reduced ICER value of $12 386 per QALY gained.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Harrington

Armstrong

Nolan

et al. 2013

Stroke

236

167

View full text Add to dashboard Cite

Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrilla tion by using novel oral anticoagulants apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg compared with warfarin. Methods-A Markov decision-analysis model was constructed using data from clinical trials to evaluate lifetime costs and quality-adjusted life-years of novel oral anticoagulants compared with warfarin. The modeled population was a hypothetical cohort of 70-year-old patients with nonvalvular atrial fibrillation, increased risk for stroke (CHADS 2 ≥1), renal creatinine clearance ≥50 mL/min, and no previous contraindications to anticoagulation. The willingness-to-pay threshold was $50 000/quality-adjusted life-years gained. Results-In

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Harrington

Armstrong

Nolan

et al. 2013

Stroke

236

167

View full text Add to dashboard Cite

show abstract

Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor–associated bleeding: Case series

Liu

Elsamadisi

Philips

et al. 2022

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

Disclaimer In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose To manage factor Xa (FXa) inhibitor–associated bleeding, andexanet alfa or 4-factor prothrombin concentrate (4F-PCC) has been used to restore hemostasis. However, literature on the outcomes for patients who received both andexanet alfa and 4F-PCC is limited. Summary We report a case series of 5 patients who received andexanet alfa plus 4F-PCC for reversal of FXa inhibitor–associated bleeding. Patients were included in this case series if they received both andexanet alfa and 4F-PCC for reversal of FXa inhibitor–associated bleeding. They were followed to either discharge or death, and in-hospital complications related to concurrent use of andexanet alfa and 4F-PCC were documented. We report an incidence of thromboembolism of 40% (2 of 5 cases) and an in-hospital mortality rate of 60% (3 of 5 cases). Taking these cases together with those in the existing literature, we found a total of 23 reported cases of safety outcomes with andexanet alfa plus 4F-PCC. The overall incidence of thromboembolism was 35% (8 of 23 cases). Conclusion This case series adds to the limited literature describing the outcomes for patients receiving andexanet alfa plus 4F-PCC. We encourage other institutions to report safety data on administering both agents.

show abstract

Letter by Freeman et al Regarding Article, “Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial”

Cited by 2 publications

References 4 publications

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor–associated bleeding: Case series

Contact Info

Product

Resources

About